AAIC 2025 Abstract
Evaluation of Self‐Mediated Alternatives for Risk Testing Education and Return of Results ‐ eSMARTER: A randomized trial from the Alzheimer’s Prevention Initiative program
By Carolyn M. Langlois, Angela R. Bradbury, Elisabeth Wood, Show 11 more authorsJessica B. S. Langbaum
Trial in peopleInterventions
Abstract
Background: Availability of amyloid modifying therapies dramatically increases the need to disclose Alzheimer’s disease (AD) related genetic and/or biomarker test results to inform clinical decision making.
